7 results
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
40, F:M 9:1 • Clinical ... Manifestations: Malar rash ... Positive in 60-80% of cases ... life-threatening • Treatment ... #Summary #rheumatology
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
CNS Manifestations ... ) Clinical Manifestations ... autoantibodies that will cause ... #rheumatology # ... cerebritis #diagnosis #management
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
to 1:1 F:M • Clinical ... NPSLE rare, Malar rash ... 40, F:M 9:1 • Clinical ... comparison #table #rheumatology ... #diagnosis #management
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
nervous system (CNS ... Petechial or purpuric rash ... erythematosus [SLE ... Treatment: • Corticosteroids ... Syndrome #Diagnosis #Management
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
overlaps with RA, SLE ... salivary ducts Clinical ... Adenocarcinoma Treatment ... Sjogrens #Syndrome #Rheumatology ... #Diagnosis #Management
Anti-NXP-2 Dermatomyositis

What?
DM with generalized subcutaneous edema
Pts have more myalgias, more severe weakness, and an increased prevalence
auricular papules Clinical ... Muscle atrophy may cause ... positive patients Treatment ... #diagnosis #management ... #rheumatology #
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
to 1:1 F:M • Clinical ... NPSLE rare, Malar rash ... is rare in DIL, SCLE-DIL ... DrugInduced #Lupus #DIL #rheumatology ... #management